斯坦福大学研究团队利用人工智能算法,从人类基因组中筛选出一种名为BRP(BPM/retinoic acid inducible neural specific 2-related peptide)的天然多肽分子,该成果为开发新一代更精准的肥胖治疗药物提供了潜在候选者 1。研究人员通过名为“Peptide Predictor”的计算机算法分析了约20,000个人类基因,预测前激素转化酶1/3的切割位点,从而将候选范围缩小至373种前激素和2,683种肽段 1。这项由Laetitia Coassolo博士领导、Katrin Svensson博士担任资深作者的研究已发表在《Nature》杂志上,相关报道发布于2026年11月4日 1。Svensson博士还联合创立了Merrifield Therapeutics公司,旨在推进这一疗法的发展 1。
与广泛作用于肠道和胰腺等组织受体的司美格鲁肽(Ozempic)不同,BRP主要特异性地作用于大脑下丘脑区域,以控制饥饿感和新陈代谢 1。在动物实验中,BRP使食物摄入量减少高达50%;在肥胖小鼠中连续注射14天后,实验组平均减重3克且几乎全为脂肪流失,而对照组增重约3克 1。此外,在测试的小鼠和小型猪中,研究人员未发现运动能力、饮水习惯、焦虑行为或粪便排出量的显著差异,这暗示BRP可能避免恶心和便秘等常见副作用 1。目前,团队正准备进行人体临床试验,以进一步验证该分子的安全性和有效性 1。
Researchers at Stanford University have utilized artificial intelligence to identify a natural peptide, known as BRP (BPM/retinoic acid inducible neural specific 2-related peptide), that suppresses appetite and promotes fat loss in animal models without triggering the gastrointestinal side effects or muscle wasting commonly associated with drugs like Ozempic 1. The study, published in Nature, details how an algorithm named "Peptide Predictor" analyzed approximately 20,000 human genes to predict cleavage sites for proprotein convertase 1/3, narrowing the candidate range to 373 prohormones and 2,683 peptides before isolating this 12-amino-acid molecule 1.
Unlike semaglutide (the active ingredient in Ozempic), which acts broadly across receptors in tissues such as the gut and pancreas, BRP specifically targets the hypothalamus region of the brain to regulate hunger and metabolism 1. In experimental trials involving obese mice, continuous injection of BRP over 14 days resulted in an average weight loss of 3 grams, consisting almost entirely of fat, while control groups gained approximately 3 grams 1. The treatment also reduced food intake by up to 50% in these animals 1. Safety assessments in both mice and mini-pigs showed no significant differences in mobility, water consumption, anxiety behaviors, or fecal output, suggesting that BRP may avoid common adverse reactions such as nausea and constipation 1.
The research was led by Dr. Laetitia Coassolo, with Dr. Katrin Svensson serving as the senior author 1. To advance the therapy toward human application, Svensson co-founded Merrifield Therapeutics 1. The team is currently preparing for clinical trials to verify the safety and efficacy of BRP in humans, positioning it as a potential next-generation candidate for precise obesity treatment 1.
评论
还没有评论,欢迎留下第一条。